Prev Arrow Stocks

Quest Diagnostics Incorporated ($DGX) Stock Forecast: Down 5.1% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is Quest Diagnostics Incorporated?

Quest Diagnostics (DGX) is a leading provider of diagnostic testing, information, and services in the United States. The company has shown strong performance over the past year, experiencing a 25.6% increase in its stock price.

Why is Quest Diagnostics Incorporated going down?

DGX stock is down 5.1% on May 21, 2025 14:45

  • Today's decline in DGX's stock price could be linked to profit-taking by investors following the recent surge.
  • The market reaction might be influenced by broader economic conditions or specific news affecting the healthcare sector, resulting in a temporary downturn for DGX.
  • Investors may be reevaluating their positions in DGX after the recent uptrend, causing a short-term decrease in the stock price.

DGX Price Chart

DGX Technical Analysis

DGX News

What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?

DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.

https://www.zacks.com/stock/news/2475104/whats-driving-quest-diagnostics-stocks-256-rally-in-a-year

0 Missing News Article Image What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?

Quest Diagnostics Incorporated Price History

30.00.2025 - DGX Stock was up 6.5%

  • The company reported strong fourth-quarter earnings and revenue that exceeded analyst expectations, showcasing robust performance in their core business.
  • Despite the positive financial results, the stock initially experienced a dip, potentially influenced by profit-taking or short-term market fluctuations.
  • Quest Diagnostics' improved margins demonstrate effective cost management and enhanced operational efficiency, which may have contributed to the positive movement in the stock.
  • Investors reacted favorably to the company's overall solid financial performance, leading to the bullish market activity observed.

30.00.2025 - DGX Stock was up 5.1%

  • Q4 earnings and revenues for Quest Diagnostics (DGX) exceeded estimates, reflecting strong financial performance.
  • The positive earnings surprise is likely to have bolstered investor confidence in the company's growth prospects.
  • Strong quarterly results may have drawn new investors and increased buying interest in DGX shares.
  • The better-than-expected performance could indicate a positive outlook for Quest Diagnostics, potentially leading to further price appreciation in the stock.

22.09.2024 - DGX Stock was up 6.2%

  • Quest Diagnostics (DGX) displayed a strong bullish movement after surpassing third-quarter financial expectations and providing positive revenue guidance for FY24.
  • The company's exceptional performance in Q3, exceeding consensus on adjusted earnings per share and showing significant year-over-year sales growth, led to a favorable market response towards DGX.
  • Optimistic future earnings growth prospects from the CEO and successful acquisition of new customers bolstered investor confidence in Quest Diagnostics.
  • The favorable reaction to Quest Diagnostics' outperformance in earnings and revenue outlook bodes well for its stock, in contrast to the modest decline in Myriad Genetics shares following a partnership announcement.

22.09.2024 - DGX Stock was up 5.2%

  • Quest Diagnostics (DGX) exceeded Q3 earnings and revenue estimates, indicating strong financial performance and investor confidence in the company's growth prospects.
  • The positive earnings surprise may have fueled investor optimism and attracted more buyers to the stock, driving the bullish movement.
  • The company's ability to outperform expectations suggests efficient management and a competitive position in the healthcare industry, contributing to the upward momentum in the stock price.
  • Overall, the market responded positively to Quest Diagnostics' robust financial results, setting a bullish tone for the stock in the near term.

19.02.2025 - DGX Stock was down 5.1%

  • Quest Diagnostics (DGX) experienced a bearish movement today.
  • Aveanna (AVAH) surging 6.2% might have diverted investor attention away from DGX.
  • The lack of positive earnings estimate revisions for Aveanna could have prompted investors to move funds out of DGX and into more promising opportunities.
  • The shift in focus towards Aveanna's potential gains may have contributed to the bearish movement in Quest Diagnostics (DGX) today.

29.03.2024 - DGX Stock was up 4.1%

  • Quest Diagnostics (DGX) received a "buy" rating and an increased stock target, reflecting positive sentiment from analysts and investors.
  • During Q1, the company experienced a notable surge in sales, surpassing estimates for adjusted EPS and achieving growth in total revenues for the first time in almost three years. This positive financial performance likely contributed to the stock's upward trend.
  • Despite beating earnings expectations, Quest Diagnostics (DGX) observed a decrease in margins in Q1, which could raise concerns among investors. Nevertheless, the overall revenue growth and strong performance overshadowed this issue, pushing the stock towards a bullish market movement.

21.04.2025 - DGX Stock was down 5.1%

  • Today's decline in DGX's stock price could be linked to profit-taking by investors following the recent surge.
  • The market reaction might be influenced by broader economic conditions or specific news affecting the healthcare sector, resulting in a temporary downturn for DGX.
  • Investors may be reevaluating their positions in DGX after the recent uptrend, causing a short-term decrease in the stock price.

23.06.2024 - DGX Stock was down 5.5%

  • Despite surpassing revenue expectations, DGX recorded a downturn in profits during the second quarter.
  • The failure to meet GAAP EPS predictions could be a factor in the stock's decline.
  • Investors' reactions may have been unfavorable due to a slight drop in reported diluted earnings per share for the quarter.
  • The market's response might also be linked to the company's adjusted diluted EPS performance and its revised full-year revenue outlook.

23.06.2024 - DGX Stock was down 5.1%

  • Despite surpassing revenue expectations and raising its 2024 outlook, Quest Diagnostics (DGX) saw a decline in its stock price.
  • The company's slight miss in GAAP EPS estimates may have influenced the negative market response, despite its strong base business growth.
  • Investors might have anticipated higher earnings per share, prompting profit-taking and a temporary stock price drop.
  • Concerns among market participants have arisen over the Q2 profit decrease, even though it outperformed estimates, indicating a potential necessity for cost management or operational enhancements for future growth.

22.03.2025 - DGX Stock was up 7.7%

  • Quest Diagnostics (DGX) stock showed a strong bullish movement.
  • The company surpassed expectations with its first quarter 2025 earnings and revenues, outperforming analyst projections.
  • The stock's upward trend can be attributed to the favorable earnings report and sustained growth over the past 5 years.
  • Investor optimism in Quest Diagnostics' performance and market position is likely driving the stock price increase.

22.03.2025 - DGX Stock was up 5.8%

  • Strong Q1 earnings and revenues exceeded expectations, signaling robust financial performance and potentially favorable future outlook.
  • Over the last 5 years, the stock has consistently outperformed the market, demonstrating steady growth and investor trust.
  • Although there was a minor decline in stock price in the past month, the significant rise over the last year indicates sustained positive momentum.
  • Anticipated earnings growth is reinforcing the bullish trend, implying ongoing profitability and investor confidence in the company's prospects.

22.03.2025 - DGX Stock was up 8.2%

  • Quest Diagnostics (DGX) experienced a robust upward movement today.
  • The company exceeded earnings expectations for the first quarter, resulting in a notable surge in its stock price.
  • Over the past 5 years, Quest Diagnostics has consistently outperformed, showcasing an impressive average annual return that has likely boosted investor confidence and interest in the stock.
  • Strong earnings and revenue results for the quarter ending in March 2025 indicate a solid performance by the company, potentially fueling additional investor confidence and driving the stock price upwards.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.